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ABSTRACT 24 
Cryptococcus spp., an important fungal pathogen, is the leading cause of fungal-25 
related mortality in human immunodeficiency virus patients, and new therapeutic 26 
options are desperately needed. Isavuconazonium sulfate, a newer triazole 27 
antifungal agent, was studied to characterize the exposure–response relationship 28 
in a rabbit model of cryptococcal meningoencephalitis. Isavuconazonium sulfate 29 
treatment was compared with fluconazole and untreated controls. Fungal burden 30 
in the cerebrospinal fluid was measured serially over time, while yeast 31 
concentrations in the brain and the eye (aqueous humor) were determined at the 32 
end of therapy. The exposure impact of isavuconazonium sulfate dosing in the 33 
rabbit was linked using mathematical modeling. Similar significant reductions in 34 
fungal burden in the brain and cerebrospinal fluid were observed with 35 
isavuconazonium sulfate and fluconazole treatment compared with untreated 36 
controls. No dose-dependent response was demonstrated with isavuconazonium 37 
sulfate treatment in this study. The treatment of cryptococcal 38 
meningoencephalitis with isavuconazonium sulfate was similar to that with 39 
fluconazole. Dose-dependent reductions in yeast over time were not 40 
demonstrated, which limited our ability to estimate the pharmacodynamic target. 41 
Further non-clinical and clinical studies are needed in order characterize the 42 
extent of the exposure–response relationship in cryptococcal 43 
meningoencephalitis. However, this study suggests isavuconazonium sulfate, like 44 
fluconazole, could be beneficial in the setting of consolidation and maintenance 45 
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therapy, rather than induction monotherapy with high burden cryptococcal 46 
meningoencephalitis.   47 
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INTRODUCTION 48 
Infections caused by Cryptococcus neoformans and C. gattii are associated 49 
with excessive morbidity and mortality in patients with and without HIV. C. 50 
neoformans is the leading cause of fungal-related mortality in HIV patients, 51 
especially in sub-Saharan Africa where the HIV/AIDS epidemic is persistent (1). 52 
At the peak of the HIV epidemic, approximately 1 million cases of cryptococcosis 53 
were reported annually in patients with AIDS (1). In the developed world, cases 54 
of cryptococcosis declined over the same time period as the use of antiretroviral 55 
therapy increased. In contrast, the prevalence remained high in low to middle 56 
income countries (2). In the United States, it is estimated that nearly 3,400 57 
hospitalizations occur yearly due to cryptococcal meningitis (3). Direct 58 
hospitalization-associated costs for cryptococcal meningitis amounted to 59 
approximately US$54 million in 2009 (3). 60 
Treatment of cryptococcal meningitis typically includes induction therapy with 61 
amphotericin B deoxycholate (0.7–1.0 mg/kg per day) or AmBisome (3–4 mg/kg 62 
per day intravenously) plus flucytosine (100 mg/kg per day orally) in four divided 63 
dosages for 1 week, followed by consolidation therapy with fluconazole (400 mg 64 
[6 mg/kg] per day orally) for a minimum of 8 weeks (4). In some areas of the 65 
world, fluconazole may be the only available agent for induction therapy (4). High 66 
baseline cerebrospinal fluid (CSF) fungal burden, altered mental status, older 67 
age, and high peripheral white blood counts predict acute 2-week mortality. 68 
Furthermore, improved outcomes were associated with amphotericin-based 69 
treatment and prompt immune reconstitution with antiretroviral therapy (5).  70 
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Cryptococcal infection generally begins in the lungs, although meningitis is 71 
the most frequently encountered clinical manifestation of cryptococcosis among 72 
those with advanced immunosuppression. The disease is more properly 73 
characterized as “meningoencephalitis” rather than meningitis since the brain 74 
parenchyma is almost invariably involved on histologic examination (6). This 75 
understanding is critical when determining a successful treatment strategy, as 76 
central nervous system (CNS) penetration into the brain tissue as well as into the 77 
CSF is vital to improve outcome. 78 
Isavuconazonium sulfate, the water-soluble prodrug of the broad-spectrum 79 
triazole antifungal agent isavuconazole, is approved by the U.S. FDA for the 80 
treatment of invasive aspergillosis and invasive mucormycosis, and by the 81 
European Medicines Agency for the treatment of invasive aspergillosis, and 82 
invasive mucormycosis in patients for whom amphotericin B is inappropriate (7, 83 
8) (9). Isavuconazole MIC values against Cryptococcus spp. range from 0.008 84 
mg/L to 0.5 mg/L with an overall modal MIC of 0.03 mg/L in a collection of more 85 
than 800 Cryptococcus neoformans isolates (10). 86 
To further support an understanding of the effectiveness of isavuconazonium 87 
sulfate against cryptococcal infections, particularly in the CNS, we characterized 88 
the exposure–response relationship of isavuconazonium sulfate in a well-89 
established rabbit model of cryptococcal meningoencephalitis caused by 90 
Cryptococcus neoformans. 91 
 92 
RESULTS 93 
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Cryptococcus neoformans (H99) MIC values. The geometric mean 94 
isavuconazole MIC value for the H99 strain of Cryptococcus neoformans was 95 
0.008 mg/L for isavuconazole and 1 mg/L for fluconazole. Yeast grown from 96 
treatment Day 8 of the isavuconazonium sulfate treatment animals showed 97 
similar MIC values. 98 
Animal model. Significant reductions in fungal burden were seen in the brain 99 
following administration of isavuconazonium sulfate doses of 83 mg/kg 100 
(equivalent to 45 mg/kg of isavuconazole) and 111.8 mg/kg (equivalent to 60 101 
mg/kg of isavuconazole). These were comparable to 80 mg/kg of fluconazole. 102 
Both isavuconazonium sulfate and fluconazole treatments resulted in significant 103 
decreases in fungal burden in the brain compared with untreated controls (P = 104 
0.0003; P = 0.0002; P = 0.0034, one-way analysis of variance (ANOVA), Holm–105 
Šidák’s multiple comparisons test) (Fig. 1a). Treatment with isavuconazonium 106 
sulfate and fluconazole resulted in significant reductions in the CSF fungal 107 
burden of yeast over time compared with controls (P < 0.0001, two-way ANOVA, 108 
Tukey’s multiple comparisons test) (Fig. 1b). Investigation of the residual fungal 109 
burden in the eye (aqueous humor) were extremely variable and were not 110 
considered reliable; therefore, the results are not reported here. 111 
Pharmacokinetics. Mean isavuconazole concentrations in the brain tissue 112 
(cerebrum, cerebellum, meninges) at the end of the experiment were similar 113 
between the isavuconazonium sulfate dose groups (Table 1). The mean ratio of 114 
brain to plasma isavuconazole concentrations in rabbits was 0.69 and 0.42 for 115 
the 83.8 mg/kg and 111.8 mg/kg doses, respectively. As with the brain tissue, the 116 
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mean isavuconazole concentrations in the CSF did not increase with increasing 117 
dose (Table 1). The mean ratio of CSF to plasma ratio was 0.044 and 0.019 for 118 
the 83.8 mg/kg and 111.8 mg/kg doses, respectively (Table 1). 119 
Pharmacokinetic/pharmacodynamic modeling. 120 
Pharmacokinetic/pharmacodynamic modeling using the brain isavuconazole 121 
concentration data and fungal burden in the CNS was not possible because of 122 
the lack of temporal data for measures. Therefore, the 123 
pharmacokinetic/pharmacodynamic model focused on a link between plasma 124 
and CSF isavuconazole concentrations and CSF fungal burden over time.  125 
The fit of the model to the plasma and CSF isavuconazole concentration data 126 
and yeast colony-forming units in the CSF over time was acceptable based on 127 
visual inspection of the median observed-versus-predicted plots. A linear 128 
regression had a coefficient of determination (r2) of 0.841 (slope = 0.951), 0.745 129 
(slope = 0.958), and 0.692 (slope = 0.853) after the Bayesian step for the 130 
isavuconazole concentrations in the plasma, CSF and CSF fungal burden, 131 
respectively (Fig. 2a, b and c). The estimates of bias and imprecision were also 132 
acceptable (plasma: −0.122 and 1.19; CSF: −0.0246 and 2.02: CSF CFU: 133 
0.00863 and 0.0207). The observed-versus-predicted plots using the mean 134 
parameter values were similar (data not shown). The mean parameter estimates 135 
are included in Table 2. 136 
The median Bayesian posterior pharmacokinetic parameters from the 137 
pharmacokinetic/pharmacodynamic model were used to estimate the area under 138 
the concentration-time curve from 0 h to 24 h (AUC0–24) for the plasma and CSF, 139 
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as well as the area under the CSF fungal burden-versus-time relationship (Table 140 
3). Although there was a nearly twofold increase in the plasma isavuconazole 141 
exposures, drug exposure in the CSF did not increase. Not surprisingly, this lack 142 
of increase in exposure by dose in the CSF compartment resulted in minimal 143 
differences in response by dose (Table 3). This lack of change in exposure and 144 
effect by dose resulted in the inability to explore and characterize the 145 
pharmacodynamic target (50% effective concentration) for response in the 146 
inhibitory sigmoid Emax model with this dataset.  147 
 148 
DISCUSSION  149 
Treatment options for cryptococcal infections are limited and the available 150 
antifungal agents have not changed substantially in the last ~20 years. It was not 151 
until recently that characterization of the exposure–response relationship with 152 
animal models and bridging studies became available to guide dosing in clinical 153 
studies (11, 12). These efforts led to modifications in sequence and duration of 154 
induction therapy, as well as changes to dosage of the three recommended 155 
agents: amphotericin B, flucytosine, and fluconazole (4). Access to all three 156 
medications in countries with limited resources—where the incidence of the 157 
infection is highest—is inconsistent (2). Fluconazole is the only agent available in 158 
some of these countries. In the current study, isavuconazonium sulfate 159 
demonstrated significant reductions in CSF and brain fungal burden in rabbits 160 
infected with Cryptococcus neoformans (H99) compared with untreated rabbits, 161 
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and similar to fluconazole. However, a dose-dependent response was not 162 
demonstrated for isavuconazole for the dosages used in this study. 163 
Isavuconazonium sulfate regimens used to treat invasive mold infections 164 
result in total drug plasma AUCs of approximately 90 mg*h/L (13). There is 165 
limited data on CNS penetration. One report that details the response of patients 166 
receiving isavuconazonium sulfate dosages ranging from 372 mg (equivalent to 167 
200 mg isavuconazole) to 1,116 mg/day (equivalent to 600 mg isavuconazole) is 168 
available (14). CSF concentrations measured during treatment are summarized 169 
in Table 4. The ratio of CSF to plasma was consistently 0.008:0.011 and did not 170 
increase with increasing dose. If one assumes similar CSF penetration from 171 
rabbits to humans, the CSF concentrations achieved with doses above 372 172 
mg/day are closer to those concentrations observed in the rabbits. Limited data 173 
are available on human brain concentrations of isavuconazole reporting a brain 174 
to plasma ratio from one patient of 0.9 (15).  175 
Given that a significant proportion of the clinical impact of cryptococcal 176 
disease in humans relates to involvement of the brain, the extent of penetration 177 
into the cerebral parenchyma is important. Data from radiolabeled 178 
isavuconazonium sulfate administered to rats show a brain to plasma 179 
concentration ratio of approximately 1.8:1 (16). A similar ratio has been reported 180 
from infected mice after receiving isavuconazonium sulfate for 14 days (17). An 181 
in vivo model of CNS disease has been conducted with isavuconazonium sulfate 182 
in mice infected with two strains of Cryptococcus neoformans (USC 1597 and 183 
H99) (17). Significant improvements in survival and reductions in fungal burden 184 
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in the cerebrum were observed with isavuconazonium sulfate treatment 185 
compared with controls and the effects were similar to treatment with 186 
fluconazole.  187 
In the clinical setting, nine patients diagnosed with cryptococcosis were 188 
treated with isavuconazonium sulfate in an open-label study (VITAL study) (18). 189 
Eight patients were alive through ≥84 days and six were considered to be 190 
treatment successes. 191 
As some yeasts persisted in the subarachnoid space for 12 days after 192 
treatment, we checked several colonies from the rabbit CSF after 8 days of 193 
treatment and there was no change in their original MICs, suggesting no 194 
evidence of direct selection for drug-resistant isolates (data not shown). Yeasts 195 
showed a non-significant reduction in the eyes following treatment with both 196 
isavuconazonium sulfate and fluconazole compared with untreated controls.  197 
The current study has several limitations. First, there was insufficient data 198 
available to understand the temporal drug exposure in the cerebrum and eyes, 199 
eliminating an ability to characterize the exposure–response relationships in 200 
these tissues. Only a single yeast strain was studied in the rabbit model, which 201 
limits an ability to understand the potential impact of pharmacodynamic variability 202 
on the clinical utility of isavuconazonium sulfate for cryptococcal meningitis. 203 
Despite these limitations, treatment with isavuconazonium sulfate and 204 
fluconazole provided similar significant reductions in cryptococcal burden in both 205 
brain and CSF. Additional preclinical and clinical studies are required to further 206 
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define the clinical utility and potential indications of isavuconazonium sulfate for 207 
cryptococcal meningoencephalitis.  208 
 209 
MATERIALS AND METHODS 210 
Organism. A clinical strain of Cryptococcus neoformans (H99) was used. 211 
H99 yeasts were stored at −80°C in 25% glycerol. Isavuconazole and 212 
fluconazole MICs were tested using the CLSI M27-A3 macrodilution 213 
methodology. Briefly, RPMI 1640 broth, using an inoculum of 0.5 × 103 to 2.5 × 214 
103 CFU/mL, was incubated for 72 h at 35°C. The endpoint for determination of 215 
the MIC was defined as ≤50% reduction in growth relative to the growth of control 216 
yeasts without drug exposure. 217 
Rabbit model of cryptococcal meningitis. Male New Zealand white rabbits 218 
weighing 2–3 kg were used; this model has been previously described (12). The 219 
Duke University IACUC approved the protocol prior to study initiation.  220 
Rabbits were individually housed and maintained with water and standard 221 
rabbit feed ad libitum. Immunosuppression was induced using hydrocortisone 222 
acetate 5 mg/kg by intramuscular injection daily starting on Day −1 and 223 
continuing through Day 13 post-infection. Rabbits were given hand-fed 224 
vegetables and supplemental subcutaneous fluids throughout the study. They 225 
were weighed daily throughout the study. Rabbits were sedated with an 226 
intramuscular injection of a mixture of ketamine (30 mg/kg) and xylazine (3 227 
mg/kg) prior to intracisternal inoculation and cisternal taps. Intravenous (i.v.) 228 
yohimbine was used to reverse the sedation, and rabbits were recovered under 229 
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supplemental heat with continuous monitoring. Prior to euthanasia, rabbits were 230 
sedated with ketamine and xylazine (40 mg/kg and 5 mg/kg, respectively).  231 
Pharmacokinetic blood collections. Collection was performed on Day 8 232 
post-infection. For pharmacokinetic blood draws, rabbits were sedated with 233 
acepromazine, 1 mg/kg, and a catheter was placed in the ear artery and sutured 234 
in place. For each blood draw, the catheter was flushed with heparinized saline. 235 
A pre-sample was then collected and discarded to remove any residual heparin 236 
and then the sample was collected from the catheter. Blood samples were taken 237 
in EDTA plasma separator tubes at the indicated timepoints post-drug 238 
administration. Plasma was isolated by centrifugation and stored at −80oC prior 239 
to testing.  240 
Pharmacokinetic Tissue collections and processing.  Brain and 241 
meningeal tissue was collected at the end of the experiment. Tissue samples 242 
were weighed and transferred to a homogenization tube. The weight was 243 
multiplied by 3 for brain and 5 for meninges to adjust the volume of the 244 
reconstitution solvent to the samples. Tissues were homogenized for 30 seconds 245 
at 4 m/s and repeated as necessary. 246 
Inoculation. C. neoformans isolate, strain H99, was grown at 30°C for 2–3 247 
days on yeast extract-peptone-dextrose (YPD) plates. A single colony was 248 
selected and a 25 mL YPD broth culture was initiated and grown for 2 days at 249 
30oC in a shaker incubator. The organisms were washed twice in phosphate-250 
buffered saline (PBS) and diluted to 3.9 × 106 cells/mL in PBS. In previous 251 
studies, we used 1 × 108 cells of C. neoformans per inoculation, but a pilot study 252 
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indicated that a lower inoculum, 1 × 106 cells, was required for a 14-day study. A 253 
volume of 0.3 mL of inoculum was loaded into 3 mL syringes with 25-gauge 254 
needles. The yeast inoculum was administered by injecting 0.3 mL 255 
intracisternally on Day −2 before dosing. The rabbits were injected with 256 
yohimbine, 0.2 mg/kg i.v. As mentioned above, rabbits were given supplement 257 
subcutaneous fluids during recovery from sedation. 258 
Treatment. Isavuconazole was administered as a water-soluble prodrug, 259 
isavuconazonium sulfate, via oral gavage. The drug was stored in sterilized glass 260 
vials at −20oC. Prior to dosing each day, an aliquot was removed and a volume 261 
of pH 4 USP-grade water was added to the aliquot to yield a solution of 60 262 
mg/mL of prodrug. Prodrug doses included 83.8 mg/kg and 111.8 mg/kg once 263 
daily, which delivered 45 mg/kg and 60 mg/kg, respectively, of isavuconazole to 264 
the animal. Fluconazole was purchased as an oral suspension and administered 265 
i.v. at a dose of 80 mg/kg per day. It was reconstituted with USP water to a final 266 
concentration of 40 mg/mL. Untreated controls received saline. Drug dosing 267 
began 48 hours post-inoculation and continued for 12 consecutive days. 268 
Fungal burden of tissue. All rabbits were humanly sacrificed after the final 269 
CSF collection, either on Day 10 or at the time of sacrifice. Brains were removed 270 
and then dissected sagittally for quantitative cultures and drug-level analysis. 271 
Fungal burden was measured in brain (cut into three sections) and eyes (vitreous 272 
humor and aqueous humor). Tissue was placed in pre-weighed tubes containing 273 
1 mL of PBS and then weighed again to find the net weight of the tissue. Tissue 274 
was homogenized using a Pro200 (Pro Scientific, Oxford, CT, USA) in a 275 
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biological safety cabinet. The tissue homogenates were 10-fold serially diluted, 276 
and then plated on YPD with chloramphenicol agar. Cultures were grown for 3 277 
days at 30°C. CFUs were quantified as the CFU/g of tissue. The fungal burden 278 
within the CSF from the subarachnoid space was measured from serial samples 279 
taken at 48, 96, 144, 192, and 240 h post-inoculation via an intracisternal tap with 280 
a 3 mL syringe and a 25-gauge needle, serially diluted (1:10), in PBS in 1 mL 281 
and plated on YPD with chloramphenicol agar, and incubated at 30°C for 2–3 282 
days, then viable yeast colonies were counted. Calculations for CFU/mL were as 283 
follows: (CFU counted × dilution)/0.1 mL. The remaining CSF was centrifuged, 284 
and the supernatant stored at −80°C. 285 
Isavuconazole bioanalytical assay. Isavuconazole concentrations in rabbit 286 
plasma, CSF and brain were measured using a Thermo Fisher Scientific 287 
Vanquish (Waltham, MA, USA) ultraperformance liquid chromatography coupled 288 
with a Thermo Fisher Scientific Q Exactive™ Focus (Waltham, MA, USA) mass 289 
spectrometer. The method used an ACE 5 C18-AR 50 × 3.0 mm (supplier: 290 
Hichrom Ltd, Reading, UK) and a 3 µL injection volume. A standard curve 291 
encompassing 15 to 40,000 ng/mL was constructed from stock solutions of 292 
isavuconazole 1 mg/mL in dimethyl sulfoxide. Chromatographic separation was 293 
achieved using gradient conditions starting with 35:65 (0.1% formic acid in water 294 
as mobile phase A, and 0.1% formic acid in acetonitrile as mobile phase B). 295 
Mobile phase B was increased to 95% from 0.2 to 1.0 min and held for 1.6 min. 296 
At 1.7 min mobile phase B was reduced to 65%. This was all at a flow rate of 0.6 297 
mL/min. Isavuconazole was detected using the exact mass in positive ion mode 298 
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(438.1195). Isavuconazole eluted after 1.0 min. The limit of detection was 15 299 
ng/mL and the assay was linear over the concentration range 15 to 40,000 300 
ng/mL. The quality control intra- and inter-day accuracy was 98.7–104.6%. The 301 
quality control coefficient of variation percentage was 1.1–8.4%. 302 
Pharmacokinetic/pharmacodynamic mathematical modeling. Population 303 
pharmacokinetic/pharmacodynamic mathematical modeling was performed using 304 
non-parametric estimation, Pmetrics™ (v. 1.5.2, University of Southern 305 
California, Los Angeles, CA, USA) (19) and fitted to the rabbit plasma and CSF 306 
isavuconazole concentration data, and the CSF CFUs. Data were weighted by 307 
the inverse of the estimated assay variance. The linked 308 
pharmacokinetic/pharmacodynamic model was constructed using the following 309 
set of differential equations: 310 
Eq. 1  
𝑑𝑋(1)
𝑑𝑡
=  −𝐾𝑎 ∙ 𝑋(1) 311 
Eq. 2  
𝑑𝑋(2)
𝑑𝑡
=  𝐾𝑎 ∙ 𝑋(1) − ((
𝐶𝑙
𝑉
) ∙ 𝑋(2)) − 𝐾𝑐𝑝 ∙ 𝑋(2) + 𝐾𝑝𝑐 ∙ 𝑋(4) − 𝐾𝑐𝑚 ∙312 
𝑋(2) + 𝐾𝑚𝑐 ∙ 𝑋(3)  313 
Eq. 3 
𝑑𝑋(3)
𝑑𝑡
=  𝐾𝑐𝑚 ∙ 𝑋(2) − 𝐾𝑚𝑐 ∙ 𝑋(3) 314 
Eq. 4 
𝑑𝑋(4)
𝑑𝑡
=  𝐾𝑐𝑝 ∙ 𝑋(2) − 𝐾𝑝𝑐 ∙ 𝑋(4) 315 
Eq. 5: 
𝑑𝑋(5)
𝑑𝑡
=  𝐾𝑔𝑚𝑎𝑥 ∙ (1 − (
(
𝑋(3)
𝑉
)
𝐻𝑔
𝐶50𝑔𝐻𝑔+(
𝑋(3)
𝑉
)
𝐻𝑔)) ∙ 𝑋(5) ∙  316 
 (1 − (
𝑋(5)
𝑝𝑜𝑝𝑚𝑎𝑥
)) − 𝑘𝑘𝑚𝑎𝑥 ∙ 𝑋(5) ∙ (
(
𝑋(3)
𝑉
)
𝐻𝑘
𝐶50𝑔𝐻𝑘+(
𝑋(3)
𝑉
)
𝐻𝑘)  317 
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The first four equations describe the pharmacokinetics of the isavuconazole, 318 
(compartment 1, theoretical absorptive compartment for oral administration; 2, 319 
central compartment; 3, CSF compartment; and 4, peripheral compartment). Cl is 320 
the clearance and defined as the amount of drug being cleared from the central 321 
compartment over time, and V is the volume of the central compartment. Ka is 322 
the first order absorption constant; Kcp, Kpc, Kcm, and Kmc are the rate 323 
constants describing the flow of drug to and from compartments 2, 3, and 4. 324 
Equation 5 describes the rate of change of the Cryptococcus yeasts as log10 325 
CFU/mL of CSF. Kgmax represents the maximum rate of growth; Hg is the slope 326 
function for growth; C50g is the amount of drug where there is half maximal 327 
growth; popmax is the theoretical maximum density of yeasts in the CSF; kkmax 328 
is the maximum rate of growth inhibition; C50k is the amount of drug where there 329 
is half maximal growth inhibition; and Hk is the slope function for growth 330 
inhibition.  331 
The final model was assessed by: a visual inspection of the observed-versus-332 
predicted concentration values plotted over time after the Bayesian step; the 333 
coefficient of determination (r2) from the linear regression of the observed-versus-334 
predicted values; and evaluation of the estimated bias (mean weighted error) and 335 
precision (adjusted mean weighted squared error). After fitting the model to the 336 
pharmacokinetic/pharmacodynamic data, the Bayesian posterior estimates for 337 
each rabbit were used to estimate the plasma and CSF concentration-time 338 
profiles for isavuconazole and the change in yeast CFUs over time in the CSF for 339 
each rabbit. CSF AUCs and the area under the log10 CFUs/mL in the 340 
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Cryptococcus spp. in the CSF over time for each rabbit were calculated by 341 
integration from the simulated concentration-time profiles (on the last day of 342 
dosing for plasma) in Pmetrics. 343 
Statistical comparisons were performed in GraphPad Prism version 8.0 344 
(GraphPad Software, San Diego, CA, USA).   345 
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FIGURES 452 
FIG 1 a-b Change in fungal burden in the rabbit. (a) Brain: All treatment groups 453 
(isavuconazonium sulfate 83.8 mg/kg and 111.8 mg/kg, and fluconazole 80 454 
mg/kg) resulted in significant reductions in log10 CFU/g in the brain at the end of 455 
treatment compared with untreated rabbits (P = 0.0003; P = 0.0002; P = 0.0034, 456 
one-way ANOVA, Holm–Šidák’s multiple comparisons test). There was no 457 
statistical difference between either isavuconazonium sulfate treatment group 458 
versus fluconazole (P > 0.05). (b) CSF: Significant changes in log10 CFUs/mL 459 
over time in CSF were demonstrated for all treatment groups (isavuconazonium 460 
sulfate 83.8 mg/kg and 111.8 mg/kg, and fluconazole 80 mg/kg) versus untreated 461 
rabbits (P < 0.0001; Tukey’s multiple comparison test). Note: Not all animals 462 
survived to Day 14.  463 
CSF, cerebrospinal fluid; ISAV, isavuconazonium sulfate; FLU, fluconazole. 464 
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FIG 2 (a) Observed versus median posterior predicted isavuconazole plasma 467 
concentrations (mg/L) from the final model after the Bayesian step (r2 = 0.841, 468 
slope = 0.951 [95% CI 0.853 to 1.050], intercept = 0.366 [95% CI −0.018 to 469 
0.751]). (b) Observed versus median posterior predicted isavuconazole CSF 470 
concentrations (mg/L) from the final model after the Bayesian step (r2 = 0.745, 471 
slope = 0.958 [95% CI 0.79 to 1.13], intercept = 0.00198 [95% CI −0.00617 to 472 
0.01010]). (c) Observed versus median posterior predicted log10 CFU/mL of CSF 473 
from the final model after the Bayesian step (r2 = 0.692, slope = 0.853 [95% CI 474 
0.69 to 1.02], intercept = 0.577 [95% CI −0.0697 to 1.22]). Dotted line is line of 475 
unity where observed equals predicted concentrations.  476 
CSF, cerebrospinal fluid. 477 
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FIG 2a 479 
 480 
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FIG 2b 482 
 483 
  484 
 o
n
 August 8, 2019 at University of Liverpool Library
http://aac.asm
.org/
D
ow
nloaded from
 
  27 
FIG 2c 485 
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Tables 487 
 488 
TABLE 1 Mean and standard deviation observed isavuconazole concentrations 489 
(mg/L) in the CNS by dose 490 
 83.8 mg/kg 111.8 mg/kg 
Brain 1.15 (±1.5) 1.31 (±0.96) 
CSF 0.08 (±0.049) 0.05 (±0.028) 
Ratio brain to plasma 0.69 (±0.69) 0.42 (±0.27) 
Ratio CSF to plasma 0.044 (±0.044) 0.019 (±0.006) 
 491 
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TABLE 2 Mean and standard deviation values for each parameter estimated 493 
from the rabbit population pharmacokinetic/pharmacodynamic-linked model 494 
Parameter (units) Mean SD 
Ka (h-1) 3.196 4.62 
Cl/F (L/h) 2.639 2.26 
Vc/F (L) 12.255 5.79 
Vb/F (L) 165.876 51.75 
Kcp (h-1) 17.942 9.82 
Kpc (h-1) 20.135 9.83 
Kcm (h-1) 13.959 13.52 
Kmc (h-1) 16.593 9.00 
Kgmax (log10 CFU/mL) 0.027 0.02 
Hg 13.670 9.13 
C50g (mg/L) 1.754 1.61 
IC (log10 CFU/mL) 28,870.429 19,162.86 
Kkmax (log10 CFU/mL) 11.168 5.19 
Popmax (log10 CFU/mL) 409,294.206 449,097.00 
Hk 3.697 2.66 
C50k (mg/L) 1.928 1.42 
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TABLE 3 Mean plasma and CSF AUC0–24 for each dose group and mean area 496 
under the log10 CFUs/mL over time of Cryptococcus spp. in the CSF 497 
 83.8 mg/kg 111.8 mg/kg 
Plasma (mg*h/L) 50.83 (±33.302) 99.83 (±31.292) 
CSF (mg*h/L) 2.87 (±2.013) 1.35 (±0.598) 
Log10 CFUs/mL versus time 1,304.36 (±240.36) 1,379.01 (±273.89) 
Decline log10 CFU/mL 1.78 (±0.69) 1.89 (±0.33) 
 498 
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TABLE 4 Plasma and CSF concentrations from two patients treated with 500 
isavuconazonium sulfate  501 
Dose Serum (mg/L) CSF (mg/L) Ratio CSF/Plasma 
Patient 1 
372 mg q24h 3.608 0.0296a 0.008 
1,116 mg q24h  11.936 0.0917a 0.008 
1,116 mg q24h 16.389 0.1312 0.008 
744 mg q24h 13.924 0.0976a 0.007 
558 mg q24h 11.749 0.109 0.009 
558 mg q24h 9.371 N/A N/A 
372 mg q24h 6.227 N/A N/A 
Patient 2 
372 mg q24h 4.489 0.0228a 0.005 
372 mg q24h 3.798 0.0405a 0.011 
 
aValues < 0.1 mg/L are extrapolated and are not actual measured drug 502 
concentrations. 503 
N/A, not available; q24h, every 24 h. 504 
Adapted from Everson et al. (14). 505 
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